|Description||This active molecular is a selective dipeptidyl peptidase 4 (DPP4) inhibitor under the development of Dong-A. Evogliptin improves insulin resistance and delays the onset of diabetes. Evogliptin monotherapy improved HbA1c, fasting plasma glucose level, OGTT results and β-cell function. In Sep 1st 2016, preclinical trials in Type-2 diabetes mellitus (Combination therapy) in Russia was on-going. In Sep 12th 2016, Phase-I clinical trials in non-alcoholic steatohepatitis (Combination therapy) in USA was on-going.|
|Synonyms||(3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-[(2-methylpropan-2-yl)oxymethyl]piperazin-2-one;CHEMBL1779710; UNII-09118300L7; DA-1229; 1222102-29-5; Evogliptin [INN]；1246960-27-9 (HCl)|
|Solubility||Soluble in DMSO|
|Application||Type-2 diabetes mellitus|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Dong-A ST; GEROPHARM; Luye Pharma Group; Tobira Therapeutics|
Talabostat mesylate is the orally bioavailable mesylate salt of an amino boronic dipeptide with antineoplastic and hematopoiesis- stimulating activities. By cle...
Dutogliptin is a selective and orally active DPP4 inhibitor. It can improve glycaemic control in patients with type 2 diabetes. But phase III clinical trials fo...
ASP-8497 free base
ASP-8497 free base is a long-acting and potent DPP-IV inhibitor. It improves glucose tolerance through glucose-dependent insulinotropic action via elevation of ...
Alogliptin is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.
Two Phase II clinical studies have been completed with Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus. Phase III clinical studies with...
Sitagliptin (MK 0431) is a potent inhibitor of DPP4 with IC50 of 19 nM in Caco-2 cell extracts. Sitagliptin is used as a hypoglycemic agent to treat type 2 diab...
ASP8497 is a long-acting and potent DPP-IV inhibitor. It improves glucose tolerance through glucose-dependent insulinotropic action via elevation of the GLP-1 l...
ASP-4000 is a dipeptidyl peptidase 4 (DPP) inhibitor. It has antihyperglycemic activity.
Sitagliptin phosphate is a potent inhibitor of DPP4 in Caco-2 cell extracts.
Omarigliptin is a potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor to be used as treatment for type 2 diabetes.
Alogliptin benzoate(SYR 322) is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.
This active molecular is a selective dipeptidyl peptidase 4 (DPP4) inhibitor under the development of Dong-A. Evogliptin improves insulin resistance and delays ...
Sitagliptin phosphate monohydrate
Sitagliptin phosphate is a potent inhibitor of DPP-IV with IC50 of 19 nM in Caco-2 cell extracts. It is used either alone or in combination with other oral anti...
Trelagliptin is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D).
Teneligliptin is a novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor. It competitively inhibited human plasma, rat plasma, and human recombinant ...
Glyptins are class of oral anti-hyperglycemic agents that inhibit dipeptidyl peptidase 4 (DPP-4), which can act as a serine exopeptidase. ASide from there use i...
Saxagliptin is a drug which was developed for the treatment of respiratory disorders such as asthma and Chronic Obstructive Pulmonary Disease (COPD). It is oral...
Saxagliptin hydrate is a selective and reversible DPP4 inhibitor. It demonstrates greater specificity for DPP4 than for either the DPP8 or DPP9 enzymes. It redu...
DBPR108 is an IC50=15 nM DPP IV inhibitor displays a more than 3000-fold selectivity over DPP8 DPP9, FAP and DPP-II. TThe in vivo effects of DBPR108, including ...
Teneligliptin hydrobromide is a novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor. It competitively inhibited human plasma, rat plasma, and human...